Search

Knowledge of the rifting and opening process of the Meso‐Tethys Ocean is important for understanding the evolution of the Tethys tectonic domain and for an in‐depth understanding of Tethys dynamics. Sedimentary rocks are faithful recorders of surface expressions of tectonic events and are thus expected to have recorded the rifting and opening of the Meso‐Tethys Ocean. This study presents petrography, sedimentology, zircon U–Pb geochronological data and Hf isotope data for the Carboniferous–Permian Shiquanhe stratigraphic succession in the Lhasa Terrane of the Tibetan Plateau. The data indicate that the 300 to 273 Ma Lagar and Angjie formations in the lower section of the Carboniferous–Permian Shiquanhe succession were deposited in the stable passive margin of northern Gondwana with sediment sources in Gondwanaland. However, the 273 to 252 Ma Xiala Formation in the upper section of the Carboniferous–Permian Shiquanhe succession was deposited in a tectonically active setting characterized by intense magmatic activity. Considering the transition from the Lagar and Angjie formations to the Xiala Formation, a significant change in depositional setting from tectonically stable to tectonically active occurred at ca 273 Ma. Similar Early–Middle Permian changes in depositional setting have also been identified in the South Qiangtang, Baoshan and Oman regions in the Tethyan tectonic domain. These widespread changes in depositional setting, together with Early–Middle Permian tectonic uplift and episodes of subsidence, as well as rift‐related magmatism in the South Qiangtang, Baoshan, Himalayan, Zagros, Oman and Turkey regions once located in northern Gondwana, constitute a complete record of continental rifting–ocean opening associated with the diachronous opening of the Meso‐Tethys Ocean during the Early–Middle Permian. [ABSTRACT FROM AUTHOR]

Polycystic ovary syndrome (PCOS), a prevalent reproductive disorder in women of reproductive age, features androgen excess, ovulatory dysfunction, and polycystic ovaries. Despite its high prevalence, specific pharmacologic intervention for PCOS is challenging. In this study, we identified artemisinins as anti-PCOS agents. Our finding demonstrated the efficacy of artemisinin derivatives in alleviating PCOS symptoms in both rodent models and human patients, curbing hyperandrogenemia through suppression of ovarian androgen synthesis. Artemisinins promoted cytochrome P450 family 11 subfamily A member 1 (CYP11A1) protein degradation to block androgen overproduction. Mechanistically, artemisinins directly targeted lon peptidase 1 (LONP1), enhanced LONP1-CYP11A1 interaction, and facilitated LONP1-catalyzed CYP11A1 degradation. Overexpression of LONP1 replicated the androgen-lowering effect of artemisinins. Our data suggest that artemisinin application is a promising approach for treating PCOS and highlight the crucial role of the LONP1-CYP11A1 interaction in controlling hyperandrogenism and PCOS occurrence.